Page last updated: 2024-11-04

oxazolam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxazolam is a benzodiazepine derivative that was originally marketed as an anxiolytic and muscle relaxant. It has been studied for its effects on anxiety, insomnia, and muscle spasms. However, due to its potential for dependence and abuse, it is no longer widely used in many countries. Oxazolam is synthesized through a multi-step process involving the reaction of a substituted benzophenone with an amino acid. Its effects are primarily mediated through the GABA receptor, which is a neurotransmitter system involved in regulating anxiety, sleep, and muscle tone. Oxazolam is still studied to understand its therapeutic potential and to develop safer and more effective alternatives.'

oxazolam: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4617
CHEMBL ID2104805
CHEBI ID31944
SCHEMBL ID10619798
MeSH IDM0040526

Synonyms (40)

Synonym
serenal
benzo(6,7)-1,4-diazepino-(5,4-b)-oxazol-6-one, 10-chloro-2,3,5,6,7,11b-hexahydro-2-methyl-11b-phenyl-
oxazolo[3,2-d][1,4]benzodiazepin-6(5h)-one, 10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyl-
oxazolam
10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyloxazolo(3,2-d)(1,4)benzodiazepin-6(5h)-one
serenal [japanese]
tranquit
einecs 246-032-0
oxazolazepam
oxazolam [inn:jan]
oxazolamum [inn-latin]
dea no. 2839
(cis,trans)-10-chlor-2,3,5,6,7,11b-tetrahydro-2-methyl-11b-phenyloxazolo(3,2-d)(1,4)benzodiazepin-6(5h)-on
cs 300
convertal
oxazolo(3,2-d)(1,4)benzodiazepin-6(5h)-one, 10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyl-
serenal (tn)
D01278
oxazolam (jp17/inn)
24143-17-7
10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyloxazolo[3,2-d][1,4]benzodiazepin-6(5h)-one
10-chloro-2-methyl-11b-phenyl-2,3,5,7-tetrahydro-[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6-one
hializan
CHEMBL2104805
unii-1v2wi2na1c
oxazolamum
1v2wi2na1c ,
10-chloro-2,3,5,11b-tetrahydro-2-methyl-11b-phenyloxazolo[3,2-d][1,4]benzodiazepin-6(7h)-one
oxazolam [jan]
oxazolam [mi]
oxazolam [mart.]
oxazolam [inn]
oxazolam [who-dd]
SCHEMBL10619798
estrone3-hemisuccinate
10-chloro-2-methyl-11b-phenyl-2,3,7,11b-tetrahydro[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6(5h)-one #
DTXSID5023401
CHEBI:31944
AKOS030242155
DB15491
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
hemiaminal etherAn organic amino compound that is a hemiaminal in which the hydrogen atom of the hydroxy group has been replaced by an organyl group. General formula: R2C(OR')NR2 ( R =/= H ). Also known as alpha-amino ethers.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (76.47)18.7374
1990's3 (17.65)18.2507
2000's1 (5.88)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.82 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index69.20 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (5.56%)4.05%
Observational0 (0.00%)0.25%
Other14 (77.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]